ETON — Eton Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1710340 ·
Last close
$63.65
Market Cap
$1.84B
52W High
$70.64
52W Low
$14.27
ADV30
569,999
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 57,925,000 | 44,301,000 | 23,013,000 | 35,249,000 | 157,273,000 | 55,628,000 | 70,350,000 |
| Jun 2026 | 37,589,000 | 25,413,000 | 12,794,000 | 11,578,000 | 115,807,000 | 26,845,000 | 69,222,000 |
| Mar 2026 | 24,266,000 | 14,735,000 | 2,414,000 | 1,554,000 | 97,710,000 | 19,661,000 | 67,095,000 |
| Dec 2025 | 21,281,000 | 13,100,000 | 2,464,000 | 1,483,000 | 92,114,000 | 25,942,000 | 65,960,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$15,135,000
Investing CF
$-15,403,000
Financing CF
$1,734,000
CapEx
$-15,124,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.38
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-99,362,000
Inventory
$10,143,000
Receivables
$24,886,000
ST Investments
—
EBIT TTM
$16,309,000
Pretax Income TTM
$12,751,000
Interest Exp TTM
$3,552,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$141,060,992
EBITDA
$47,665,000
Free Cash Flow
$8,321,625
Enterprise Value
$1,596,889,472
Total Cash
$55,628,000
Total Debt
$24,086,000
Shares Out
28,842,215
Trailing EPS
$1.54
Book Value
$3.02
ROE
90.6%
ROA
20.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 79,950,000 | -844,000 | -4,601,000 | 92,114,000 | 65,960,000 | 26,154,000 | 10,524,000 |
| Dec 2024 | 39,011,000 | -2,597,000 | -3,823,000 | 76,123,000 | 51,695,000 | 24,428,000 | 969,000 |
| Dec 2023 | 31,642,000 | -1,192,000 | -936,000 | 31,740,000 | 16,263,000 | 15,477,000 | 6,815,000 |
| Dec 2022 | 21,251,000 | -8,260,000 | -9,021,000 | 25,030,000 | 11,952,000 | 13,078,000 | 4,821,000 |
TTM Snapshot
Revenues TTM
$105,595,000
NetIncome TTM
$12,688,000
OpCashFlow TTM
—
Assets (Latest)
$115,807,000
Forward EPS
$3.31
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRAX | First Tracks Biotherapeutics, Inc. | $1.83B | $43.57 | — |
| HMDCF | HUTCHMED (China) Ltd | $1.88B | $2.16 | — |
| ZBIO | Zenas BioPharma, Inc. | $1.88B | $27.75 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.79B | $29.89 | — |
| ZYME | Zymeworks Inc. | $1.78B | $25.84 | — |
News headlines (Yahoo Finance, 1h cache)
Explosive Growth Ignites This Biotech. But There's A Catch.
2026-11-18 21:07 · Yahoo
Eton Pharmaceuticals (ETON) Stock Looks Above Fair Value On Earnings
2026-11-11 13:07 · Yahoo
Eton Pharmaceuticals (ETON) Unveils ET 900 And Shares Early ET 700 Clinical Data
2026-11-11 12:14 · Yahoo
Is Eton Pharmaceuticals (ETON) Still Below Fair Value As Earnings And Guidance Impress?
2026-11-11 05:16 · Yahoo
Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion
2026-11-06 08:27 · Yahoo
Eton Pharma (ETON) Q3 2026 Earnings Call Transcript
2026-11-06 07:29 · Yahoo
Eton Pharmaceuticals Inc (ETON) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised ...
2026-11-06 07:22 · Yahoo
Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass Estimates
2026-11-06 00:00 · Yahoo
Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
2026-11-05 21:05 · Yahoo
Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability
2026-11-05 21:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.